We all know AI is transforming software. But one of the areas where AI is starting to deliver truly revolutionary results is perhaps the least-discussed: biotechnology. And one of the most compelling examples of this transformation is growing in Dublin — its name is Nuritas.
A Dublin AI–Science Discovery
Nuritas was founded in 2014 by Dr. Nora Khaldi in Dublin. The company’s headquarters is still on Dawson Street today, and with a 73-person team, it continues to write one of Europe’s most notable success stories at the intersection of AI and biotech.
Khaldi’s core insight was simple but powerful: nature has been hosting biologically active molecules — particularly peptides (short chains of amino acids that make up proteins) — that support human health for millions of years, yet most of them remain undiscovered. If AI could systematically surface these peptides from plant and protein sources, an entirely new ingredient library could open up for the health industry.
This insight gave birth to AI Magnifier — Nuritas’s proprietary technology that uses AI to accelerate peptide discovery.
Why Dublin?
Dublin’s significance to Nuritas goes well beyond being a place of founding. Ireland is both one of Europe’s AI talent pools and one of Europe’s leading hubs in life sciences. Computational and bioinformatics programs at universities like Trinity College, UCD, and DCU make it possible for companies like Nuritas to build teams working at the intersection of AI and biochemistry.
Nuritas is among the companies that best represent this dual ecosystem advantage Dublin offers — technology + biotechnology — making it a flagship example of Dublin AI biotech.
Recent Milestones
Vitafoods Europe 2026 (May 5–7). As of this week, Nuritas is at the Vitafoods Europe trade show in Barcelona, Stand 5D30. Being at center stage at Europe’s largest gathering for the functional food and nutraceutical sectors clearly signals the company’s positioning in the European B2B market.
Three New European Distributor Partnerships. The strategic partnerships announced at Vitafoods take Nuritas’s products to a much broader European B2B (business-to-business) market in a single move:
- Alifarma — Spain and Portugal markets
- Faravelli — Italy market
- Vivatis Pharma — Poland, Czech Republic, Slovakia, and the Baltic countries (Estonia, Latvia, Lithuania)
Liverpool John Moores University Clinical Collaboration. Nuritas is running a new double-blind randomised controlled trial (RCT — the most reliable scientific testing method) registered as NCT07528469. The study, which measures PeptiStrong®’s effects on muscle strength and functional performance in 80 healthy adults aged 60–85, significantly strengthens the scientific foundation in healthy aging.
$42 Million Series C. Nuritas raised $42 million in its Series C (third-round growth funding) to scale its AI-powered peptide discovery platform. The company’s investor and advisor network includes global names such as Indra Nooyi (former PepsiCo CEO), Bono, and Marc Benioff.
What’s Next
Nuritas’s roadmap for the coming period progresses on four axes: running AI Magnifier across larger peptide libraries, taking the clinical evidence accumulated around PeptiStrong® into different age and health segments, gaining new B2B customers in Europe, and growing the Dublin-based AI + life-sciences team.
All of this movement says one thing for AI Dubliners: Dublin isn’t just a city where tech giants set up offices — it’s a hub that grows its own global biotech pioneers.
Following Nuritas’s story isn’t just watching a company succeed; it’s also observing how Dublin’s AI ecosystem has gained multi-layered depth. And this story — with the new chapter it took on the Vitafoods stage this week — is still at its starting point.
For more information:
